The Impact of Glucomannan, Inulin, and Psyllium Supplementation (Soloways^TM) on Weight Loss in Adults with FTO, LEP, LEPR, and MC4R Polymorphisms: A Randomized, Double-Blind, Placebo-Controlled Trial.

"Conflicts of Interest Authors Evgeny Pokushalov, Michael Johnson, Claire Garcia and Richard Miller are employed by the company Scientific Research Laboratory, Triangel Scientific. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

"The authors declare that this study, S.Lab (SOLOWAYS), a pharmaceutical company, contributed solely by manufacturing the supplements used in the research. S.Lab (SOLOWAYS) did not participate in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication."

"We conducted a randomized, double-blind, parallel-group clinical trial in which a single supplement regimen, containing a combined formulation of glucomannan, inulin, and psyllium fibers, was compared to a placebo. The study protocol was approved by the local ethics committee and conducted in accordance with standard institutional operating procedures and the Declaration of Helsinki. All participants enrolled in the study provided written informed consent. The study was registered with ClinicalTrials.gov (NCT06188832)."